by Nicholas Jackson | drugtargetreview.com
Plans for the world’s first clinical trial for a vaccine targeting Alzheimer’s disease-like characteristics in those with Down’s syndrome have been announced. The study will test AC Immune’s vaccine ACI-24 and is being conducted in collaboration with the University of California, San Diego (UC San Diego) Down’s Syndrome Research and Treatment Center. Funding is provided by a significant grant from the US National Institutes of Health (NIH) and an additional grant from the LuMind Research Down’s Syndrome Foundation. This is the first public/private collaboration for a clinical trial in the field of Down’s syndrome.